色多多下载官方版_色多多app最新版下载_色多多深夜福利免费观看_色多多网站入口官方版下载

TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
Emerging industries supporting the increase or decrease change: drug related three directions worthy of attention
 
Author:中國銘鉉 企劃部  Release Time:2017-2-23 8:41:26  Number Browse:964
 
Medical network - February 22 in February this year, the national development and reform commission released 2016 "catalog for the guidance of strategic emerging industries focus on products and services (hereinafter referred to as the" 2017 version of the directory "). Compared with 2013 version of the directory seven industries, 24 key strategic emerging industry development under the direction of 125 is a direction, a total of more than 3100 segment of the products and services; 2017 a total of five major areas of eight industries (separately) related services, mainly under the direction of 40, 174 is a direction, nearly 4000 niche products and services, the state supports to further expand the scope of. 
 
Related to drugs, mainly involved in cross-border industry, biological medicine industry and large health three direction, the author further compared to the 2017 edition and 2013 edition directory, from reading to maintain and increase or decrease in content. 
 
 
 
Cross-border industries: the first mention of "data pharmaceutical" concept 
 
2017 directory, "information technology services" for the first time to separate direction "' + 'Internet application service", "Internet +" profit people service in medical service is one of them. 
 
In the 2013 version of the directory, the national development and reform commission more is expected in the Internet of information awareness, information transmission, information processing ability, on the basis of medical treatment can be combined with Internet application service, provide for the health care industry and the public service. 2017 version of the directory for this support. 
 
2013 version of the directory for the "public information service" in the "medical information service" have specific indicators, including regional medical and health information services, remote medical service, integration of value-added services, hospitals, health services and basic medical and health institutions information system. Medical information service is the main component content regional residents electronic health records, electronic medical records, prescription, cloud computing services, third party inspection check, health management, drug distribution. "Medical information service" in the end no version of the directory in 2017 include, perhaps related to "electronic prescription" stop. Regional residents electronic health records and electronic medical records has been active in building, and personal medical care account linkage, this part should belong to "Internet +" medical profit people service. 
 
In fact, the 2013 edition advocate of remote medical service (that is, the large and medium-sized cities and remote areas of the third class hospitals grassroots health institutions based on the information network of medical cooperation) has a lot of cases. Such as wuzhen Internet hospital, micro medical Internet hospital in sichuan, gansu, guangxi Internet hospital Internet hospital, ningbo cloud hospital, ali health network hospital, Shanghai children's hospital, zhejiang university, a school Internet Internet, etc. Institute, arterial network, according to tencent eggshell institute jointly issued the "2016 white paper on China's Internet hospital, as of November 2016, the national army of Internet hospital has expanded to about 36. 
 
2017 version of the directory mentioned "big data service" for the first time in the direction of the first "data pharmaceutical" concept. As a kind of new formats was placed on the new mode to support the content, the key is to use the distributed parallel computing, artificial intelligence technology to huge amounts of heterogeneous data calculation, analysis and mining, the application of the information and knowledge of the output in pharmaceutical production. 
 
2017 the first mention of "artificial intelligence" under the direction of "artificial intelligence system" direction, will also health care application system of the artificial intelligence industry to key development areas. 
 
Biological medicine industry: look from the increase or decrease in the content resources 
 
Content for biological medicine industry as a whole, the 2017 edition and 2013 edition directory difference, mainly is the individual content of fine-tuning. As can be seen from the fine-tuning of the national development and reform commission for the different classification product support policy changes - most of continuation of existing policies, to clinical and quality improvement direction resources required. 
 
"New vaccine didn't mention" "vaccine production with clean animals, cell substrate, medium, such as" content, this part move to "biomedical critical equipment and raw materials". 2017 version of the directory "biomedical critical equipment and raw materials" corresponding to the 2013 version of the directory of "biological separation medium and medicinal supplementary material. 
 
"Biotech drugs" will "polypeptide drugs" and "polypeptide drugs large-scale synthesis technology" "restructuring clotting factors, genetic recombinant albumin. 
 
"Made chemicals and active pharmaceutical ingredients" no longer includes the help antitumor drugs "content, new" childhood diseases treatment of new drugs, 'the orphan diseases' treatment ". No longer support the auxiliary medicine and resources tilt to the children's drugs, with the current national health development planning commission and advocate people club department of medical institution clinical medicine guidelines. 
 
"Modern Chinese medicine and national medicine" didn't include "Chinese medicine health product development research" and "authentic rare and endangered species protection, alternative research, construction and shortage of traditional Chinese medicinal materials quality provenance breeding and standardization planting, breeding, well-bred breeding system of Chinese drugs and Chinese herbal medicine planting standardization, large-scale production base, construction of traditional Chinese medicine (TCM) germplasm and active component repository, perfection has important economic value of China's unique animal medicine germplasm from insects and active component repository construction and farming key technologies and the related standard of quality management of construction, in traditional Chinese medicine resources monitoring and information network construction, set up unique medicinal insects animals endangered resource protection information network"; New "Chinese herbal medicine pesticide residues, heavy metals and harmful elements such as safety margin" and "Chinese medicine system of green manufacturing, intelligent manufacturing technology and equipment development. Chinese medicine yinpian processing technology and traditional Chinese medicine quality control technology and equipment". The management of national administration of GAP certification for quality management of traditional Chinese medicine support is no longer a source production base, but prefer to result oriented, quality testing data prove that the drug is safe and effective. 
 
"Biological medicine service" increase "biological", "medical health data, data sharing platform", and "precision for personalized health care and medical genetic testing services, online intelligent diagnosis and treatment of the combination of ecological system, aiming at the biological treatment of major difficult and complicated service", advocate with "big data", "precision medical" combined development of personalized treatment. 
 
The whole part to delete "Marine biological medicine", this means that no longer emphasizes whether source from Marine organisms, relevant supporting content in other parts of the basic coincidence. 
 
Big health: focus on "food" "Marine bioactive substances and biological products" 
 
Under the direction of "biological agriculture industry" new direction "biological food". Support includes "including food omics technology, bioactive factors targeting biological separation and extraction technology, food, synthetic biology engineering technology, food, biological efficient conversion technology, gut microbes macro genomics technology, molecular food, precise nutritious food". 
 
And expect to focus on big health transformation healthy enterprise, in view of the "traditional Chinese medicine health product development research" is no longer supported, relevant enterprises can focus on accurate nutrition food, the concept is similar to traditional Chinese medicine "cure not ill", mainly through the combination of genetic science and food science, food nutrition, targeted design precision manufacturing individuation food. Its development will also require large data integration, gene science, nutrition, classic medical information such as the gut. 
 
2013 directory has advocated the "Marine bioactive substances and biological products" direction, also a big health the direction of the layout. Such as natural carotenoids such as astaxanthin, lutein, natural pigment, such as algae flavin polyunsaturated fatty acids such as docosahexaenoic acid and eicosapentaenoic acid, protease, lipase, cellulase and so on new enzymes, ocean Marine functional proteins, peptides and oligonucleotides sugars, such as Marine algae extract active ingredient, are 2013 and 2017, both support content. 2017 directory also add support "green preparation technology, chitosan oligosaccharides and their derivatives". 
 
Previous article:The national big inspection! To look up nearly 5 m medical equipment companies and hospitals
Next article:Three health sector reform of payment Gradually reduce pay according to the project
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粵公網(wǎng)安備 44011202000029號